Page 68 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

doi: 10.1016/j.biomaterials.2023.122028 352. Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z. Nanotechnology-
based strategies for treatment of ocular disease. Acta
340. Tarantino G, Saldalamacchia G, Conca P, Arena A.
Non-alcoholic fatty liver disease: Further expression Pharm Sin B. 2017;7(3):281-291.
of the metabolic syndrome. J Gastroenterol Hepatol. doi: 10.1016/j.apsb.2016.09.001
2007;22(3):293-303.
353. Mun EA, Morrison PW, Williams AC, Khutoryanskiy VV.
doi: 10.1111/j.1440-1746.2007.04824.x On the barrier properties of the cornea: A microscopy
study of the penetration of fluorescently labeled
341. Williams DL. Oxidative stress and the eye. Vet Clin North
Am Small Anim Pract. 2008;38(1):179-192, vii. nanoparticles, polymers, and sodium fluorescein. Mol
Pharm. 2014;11(10):3556-3564.
doi: 10.1016/j.cvsm.2007.10.006
doi: 10.1021/mp500332m
342. Subramaniam MD, Iyer M, Nair AP, et al. Oxidative stress
and mitochondrial transfer: A new dimension towards 354. Pascolini D, Mariotti SP. Global estimates of visual
ocular diseases. Genes Dis. 2022;9(3):610-637. impairment: 2010. Br J Ophthalmol. 2012;96(5):614-618.
doi: 10.1136/bjophthalmol-2011-300539
doi: 10.1016/j.gendis.2020.11.020
355. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related
343. Hsueh YJ, Chen YN, Tsao YT, Cheng CM, Wu WC, Chen
HC. The pathomechanism, antioxidant biomarkers, and macular degeneration. Lancet. 2012;379(9827):1728-1738.
treatment of oxidative stress-related eye diseases. Int J Mol doi: 10.1016/S0140-6736(12)60282-7
Sci. 2022;23(3):1255. 356. Bowes Rickman C, Farsiu S, Toth CA, Klingeborn M.
doi: 10.3390/ijms23031255 Dry age-related macular degeneration: Mechanisms,
therapeutic targets, and imaging. Invest Ophthalmol Vis
344. Tang Z, Fan X, Chen Y, Gu P. Ocular nanomedicine. Adv Sci. 2013;54(14):ORSF68-ORSF80.
Sci (Weinh). 2022;9(15):e2003699.
doi: 10.1167/iovs.13-12757
doi: 10.1002/advs.202003699
357. Chappelow AV, Kaiser PK. Neovascular age-related macular
345. Cunha-Vaz JG. The blood-ocular barriers: Past, present,
and future. Doc Ophthalmol. 1997;93(1-2):149-157. degeneration: Potential therapies. Drugs. 2008;68(8):1029-1036.
doi: 10.2165/00003495-200868080-00002
doi: 10.1007/BF02569055
358. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology
346. Freddo TF. Shifting the paradigm of the blood-aqueous
barrier. Exp Eye Res. 2001;73(5):581-592. of age-related macular degeneration. Am J Ophthalmol.
2004;137(3):486-495.
doi: 10.1006/exer.2001.1056
doi: 10.1016/j.ajo.2003.11.069
347. Runkle EA, Antonetti DA. The blood-retinal barrier: 359. Wong WL, Su X, Li X, et al. Global prevalence of age-related
Structure and functional significance. In: Nag S, editor.
The Blood-Brain and Other Neural Barriers: Reviews and macular degeneration and disease burden projection for
2020 and 2040: A systematic review and meta-analysis.
Protocols. United States: Humana Press; 2011. p. 133-148.
Lancet Glob Health. 2014;2(2):e106-e116.
348. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection doi: 10.1016/S2214-109X(13)70145-1
of therapeutic agents. Retina. 2009;29(7):875-912.
360. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of
doi: 10.1097/IAE.0b013e3181a94f01
oxidative stress in the pathogenesis of age-related macular
349. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: degeneration. Surv Ophthalmol. 2000;45(2):115-134.
A state of the art. J Control Release. 2012;161(2):628-634.
doi: 10.1016/s0039-6257(00)00140-5
doi: 10.1016/j.jconrel.2012.01.019
361. Wang P, Chin EK, Almeida D. Antioxidants for the
350. Falavarjani KG, Nguyen QD. Adverse events and treatment of retinal disease: Summary of recent evidence.
complications associated with intravitreal injection of Clin Ophthalmol. 2021;15:1621-1628.
anti-VEGF agents: A review of literature. Eye (Lond). doi: 10.2147/OPTH.S307009
2013;27(7):787-794.
362. Luo LJ, Jian HJ, Harroun SG, Lai JY, Unnikrishnan B,
doi: 10.1038/eye.2013.107
Huang CC. Targeting nanocomposites with anti-oxidative/
351. Wang C, Pang Y. Nano-based eye drop: Topical and inflammatory/angiogenic activities for synergistically
noninvasive therapy for ocular diseases. Adv Drug Deliv alleviating macular degeneration. Appl Mater Today.
Rev. 2023;194:114721. 2021;24:101156.
doi: 10.1016/j.addr.2023.114721 doi: 10.1016/j.apmt.2021.101156

Volume 1 Issue 1 (2024) 62 doi: 10.36922/imo.2527